Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.31 -0.19 (-1.03%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

January 06, 2023

These biotechnology stocks are pushing ahead with promising innovations.

Via The Motley Fool

Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate

January 05, 2023

From Catalent, Inc.

Via Business Wire

BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know ↗

December 22, 2022

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

November 03, 2022

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:

Via Benzinga

Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript ↗

November 03, 2022

SRPT earnings call for the period ending September 30, 2022.

Via The Motley Fool

7 Analysts Have This to Say About Sarepta Therapeutics ↗

October 13, 2022

Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:

Via Benzinga

Analyst Ratings for Sarepta Therapeutics ↗

September 08, 2022

Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:

Via Benzinga

2 Top Healthcare Stocks to Buy for the Long Haul ↗

December 09, 2022

These two companies are just getting started.

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy ↗

November 28, 2022

Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.

Via Investor's Business Daily

3 Unstoppable Stocks That Could Double in 5 Years ↗

October 29, 2022

The opportunities for these innovators are tremendous.

Via The Motley Fool

2 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

October 19, 2022

These two drugmakers are growing in prominence.

Via The Motley Fool

FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial ↗

September 06, 2022

Via Benzinga

Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications ↗

August 08, 2022

Via Benzinga

Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts ↗

August 03, 2022

Via Benzinga

Earnings Scheduled For November 2, 2022 ↗

November 02, 2022

Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.

Via Benzinga

Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71% ↗

October 17, 2022

Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.

Via Benzinga

Is Pfizer Stock Still Worth Buying After the Pandemic?

October 12, 2022

Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.

Via MarketBeat

Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors

September 29, 2022

Via AB Newswire

A Trio of Q3 Winners With Room to Run

September 29, 2022

It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside.

Via MarketBeat

Topics Economy Stocks

PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst ↗

September 28, 2022

Via Benzinga

$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying ↗

September 16, 2022

Although US stocks closed lower on Thursday, there were a few notable insider trades.

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16% ↗

September 08, 2022

Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.

Via Benzinga

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome ↗

August 30, 2022

Not all shares are slowing down alongside the industry group.

Via Investor's Business Daily

Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play ↗

August 08, 2022

Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and...

Via Benzinga

Sarepta Therapeutics: Q2 Earnings Insights ↗

August 02, 2022

Sarepta Therapeutics (NASDAQ:SRPT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sarepta Therapeutics...

Via Benzinga

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

< Previous 1 2

...

28 29 30 31 32 33 34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today